-
公开(公告)号：EP3946363A2
公开(公告)日：2022-02-09
申请号：EP20717107.5
申请日：2020-03-27
申请人： Novo Nordisk A/S
发明人： HOEG-JENSEN, Thomas , BEHRENS, Carsten , CLÓ, Emiliano , MÜNZEL, Martin, Werner, Borchsenius , SAUERBERG, Per , KRUSE, Thomas , SPETZLER, Jane , SENSFUSS, Ulrich , HJØRRINGGAARD, Claudia, Ulrich , THØGERSEN, Henning , BALSÁNEK, Vojtech , DROBNÁKOVÁ, Zuzana , DROZ, Ladislav , HAVRÁNEK, Miroslav , KOTEK, Vladislav , STENGL, Milan , SNAJDR, Ivan , VÁNOVÁ, Hana
-
公开(公告)号：EP2758426A1
公开(公告)日：2014-07-30
申请号：EP12759773.0
申请日：2012-09-21
申请人： Novo Nordisk A/S
发明人： LAU, Jesper, F. , KRUSE, Thomas , THØGERSEN, Henning , SENSFUSS, Ulrich , NIELSEN, Peter, Kresten
IPC分类号： C07K14/605 , A61K38/00
CPC分类号： C07K14/605 , A61K38/00 , A61K38/2278 , A61K38/26
摘要： The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
-
公开(公告)号：EP2448962A1
公开(公告)日：2012-05-09
申请号：EP10726515.9
申请日：2010-06-29
申请人： Novo Nordisk A/S
发明人： HOEG-JENSEN, Thomas , JAKOBSEN, Palle , SENSFUSS, Ulrich , FLEDELIUS, Christian , RIBEL-MADSEN, Ulla
摘要： The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.
-
公开(公告)号：EP2106406A2
公开(公告)日：2009-10-07
申请号：EP08707961.2
申请日：2008-01-17
申请人： Novo Nordisk A/S
发明人： SENSFUSS, Ulrich
CPC分类号： C07K14/68
摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
-
公开(公告)号：EP1809666A2
公开(公告)日：2007-07-25
申请号：EP05801398.8
申请日：2005-11-04
申请人： Novo Nordisk A/S
IPC分类号： C07K14/68
摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
摘要翻译： 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，涉及该化合物在治疗中的用途，涉及包括将该化合物给予有需要的患者的治疗方法，以及涉及 化合物在药物制造中的应用。 本发明化合物在治疗肥胖以及与肥胖有关的各种疾病或病症方面特别有意义。
-
公开(公告)号：EP3204408B1
公开(公告)日：2020-05-06
申请号：EP15778311.9
申请日：2015-10-09
申请人： Novo Nordisk A/S
发明人： REEDTZ-RUNGE, Steffen , SENSFUSS, Ulrich , KRUSE, Thomas , SPETZLER, Jane , THØGERSEN, Henning , WENZEL TORNØE, Christian , LAU, Jesper F.
IPC分类号： C07K14/605 , A61K38/26
-
公开(公告)号：EP2758426B1
公开(公告)日：2019-08-07
申请号：EP12759773.0
申请日：2012-09-21
申请人： Novo Nordisk A/S
发明人： LAU, Jesper, F. , KRUSE, Thomas , THØGERSEN, Henning , SENSFUSS, Ulrich , NIELSEN, Peter, Kresten
IPC分类号： C07K14/605 , A61K38/00
-
8.发明公开GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE 审中-公开GLP-1 / GLUCAGON-REZEPTOR-COAGONISTEN ZUR MEDISINISCHEN VERWENDUNG
公开(公告)号：EP3151852A1
公开(公告)日：2017-04-12
申请号：EP15725074.7
申请日：2015-06-03
申请人： Novo Nordisk A/S
发明人： SENSFUSS, Ulrich , LAU, Jesper F. , KRUSE, Thomas
IPC分类号： A61K38/26 , C07K14/605 , A61K47/50
CPC分类号： C07K14/605 , A61K38/00 , A61K38/28 , A61K2300/00
摘要： The present invention relates to novel glucagon derivatives which are GLP-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.
摘要翻译： 本发明涉及GLP-1 /胰高血糖素受体共激动剂的新型胰高血糖素衍生物，以及所述胰高血糖素衍生物在医药中的用途，例如治疗糖尿病，肥胖症及相关疾病和病症。
-
9.发明公开STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE 审中-公开稳定剂，ZEITVERZÖGERTECOAGONISTEN DES GLP-1- / GLUCAGON-REZEPTORS ZUR MEDISINISCHEN VERWENDUNG
公开(公告)号：EP2986313A1
公开(公告)日：2016-02-24
申请号：EP14719715.6
申请日：2014-04-22
申请人： Novo Nordisk A/S
发明人： SENSFUSS, Ulrich , KRUSE, Thomas , LAU, Jesper F.
IPC分类号： A61K38/26 , A61K47/48 , C07K14/605
CPC分类号： C07K14/605 , A61K38/26 , A61K38/28
摘要： The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
摘要翻译： 本发明涉及新型稳定和延长的GLP-1 /胰高血糖素受体共激动剂，在治疗中使用所述肽，包括向患者施用所述肽的治疗方法，以及所述肽在制备中的用途 药物。
-
公开(公告)号：EP2104684A1
公开(公告)日：2009-09-30
申请号：EP08707960.4
申请日：2008-01-17
申请人： Novo Nordisk A/S
发明人： SENSFUSS, Ulrich , LAU, Jesper
CPC分类号： C07K14/68
摘要： The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
摘要翻译： 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，涉及该化合物在治疗中的用途，涉及包括将该化合物给予有需要的患者的治疗方法，以及涉及 化合物在药物制造中的应用。 本发明化合物在治疗肥胖以及与肥胖有关的各种疾病或病症方面特别有意义。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.022 秒)
